Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. PRODUCT MONOGRAPH. BYETTA® exenatide injection. µg/mL. mL prefilled pen (60 doses of 5 µg/dose) and. mL prefilled pen.
|Published (Last):||11 May 2018|
|PDF File Size:||20.75 Mb|
|ePub File Size:||10.11 Mb|
|Price:||Free* [*Free Regsitration Required]|
Therefore, careful monitoring of blood glucose is recommended when quinolones and antidiabetic agents are co-administered. Blood glucose should be closely monitored and antidiabetic agents adjusted accordingly in this situation. The main risk factors for impaired glucose tolerance due to corticosteroids are the dose of steroid and duration of treatment.
Moderate Niacin nicotinic acid interferes with glucose metabolism and can result in hyperglycemia. Extended-release exenatide is not a first-line therapy for patients inadequately controlled on diet and exercise.
Welcome to BYETTA.com!
The presence or absence of a concomitant progestin may influence the significance of any hormonal effect on glucose homeostasis. The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is Patients should be aware of the need to have a readily byeta source of glucose dextrose, d-glucose or other carbohydrate to treat hypoglycemic episodes.
In severe hypoglycemia, intravenous dextrose or glucagon injections may be needed. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. The clinical effects of these competing mechanisms are not known.
It may have direct beta-cell toxicity; the effects may be dose-related. Hold the autoinjector upright with the orange cap toward the ceiling.
Minor Loop diuretics, such as bumetanide, furosemide, and torsemide, may cause hyperglycemia and glycosuria in patients with diabetes mellitus, probably due to diuretic-induced hypokalemia. Patients should be advised to eat within 20 minutes of mecasermin administration. Staying Active Learn how regular physical activity can help you manage type 2 diabetes.
Minor Diazoxide, when administered intravenously or orally, produces a prompt dose-related increase in blood glucose level, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect.
Official BYETTA® (exenatide) injection Healthcare Professional Website
Taking an oral contraceptive at least 1 hour before an incretin mimetic injection should reduce the risk of an effect on contraceptive or hormonal absorption. For lixisenatide, the manufacturer recommends pakage the OC 1 hour before injection or 11 hours after injection to reduce the effect on absorption. Consideration should be given to alternative antidiabetic therapy in patients with a history of pancreatitis.
An insulin glargine dose titration algorithm is in the exenatide package insert. Monitor blood glucose closely during coadministration. No placebo-treated patients withdrew due to nausea or vomiting. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues e.
May be used as monotherapy or with other antidiabetic medications. Pen needles for the Byetta Pen are not included and must be purchased separately. Moderate Salicylates, by inhibiting prostaglandin E2 synthesis, can indirectly increase insulin secretion.
First-phase insulin byetya release of insulin within 10 minutes following a glucose load is lost in patients with type 2 diabetes. Post-marketing reports of acute pancreatitis in patients taking exenatide have been reported, including necrotizing or hemorrhagic pancreatitis.
If a patient develops hypoglycemia during treatment, adjust anti-diabetic drug regimen accordingly. Tolbutamide has usually been considered compatible with breast-feeding. Moderate Paxkage blood glucose levels regularly in patients with diabetes, especially when pasireotide treatment is pacage or when the dose is altered.
A green shield will pop up after the cap is removed; the green shield hides the needle. Patients with diabetes treated with pegvisomant and antidiabetic agents may be more likely to experience hypoglycemia. A decreased dose of the antidiabetic agent may be necessary as severe hypoglycemia has been reported in patients treated concomitantly with chloroquine and an antidiabetic agent.
However, incretin mimetics have been shown to slow gastric emptying.